297. Safety of Repeat Intracerebral Administration of MV-CEA in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas
Rae Myers(Mayo Clinic in Arizona), Galanis Evanthia(Mayo Clinic in Arizona), Diane Soeffker(Mayo Clinic), Goerss J. Stephan(Mayo Clinic), Suzanne Greiner(Mayo Clinic in Arizona), Federspiel J. Mark(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Mary Harvey(Mayo Clinic in Arizona), Russell J. Stephen(Mayo Clinic), Steven E. Shelton(UW Health University Hospital), Paula J. Zollman(Mayo Clinic), Corey Raffel(University of California, San Francisco), Peng Kah-Whye(Mayo Clinic), Kaufmann J. Timothy(Mayo Clinic)
Cited by 5
Related Papers
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
|The Journal of Immunology|2011|250
Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19
|The Journal of Experimental Medicine|2021|232
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
|Cancer Research|2017|169
Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
|Cancer Research|2014|156
Airway exposure initiates peanut allergy by involving the IL-1 pathway and T follicular helper cells in mice
|Journal of Allergy and Clinical Immunology|2017|142